Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Lepu Biopharma CoHKSE:02157 -3.04%45 PS Ratio is 6.15 as of Aug. 24, 2026, which is 74% below its 10-year median of 23.42. GuruFocus rates HKSE:02157 with a GF Score™ of 45/100 and a GF Value™ of HK$16.73 (Possible Value Trap). The stock has 6 warning signs investors should review. Among 932 Biotechnology companies, Lepu Biopharma Co ranks better than 60.84% on this metric.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. As of today, Lepu Biopharma Co's share price is HK$3.83.
Lepu Biopharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.62. Hence, Lepu Biopharma Co's PS Ratio for today is 6.15.
Good Sign:
Lepu Biopharma Co Ltd stock PS Ratio (=6.72) is close to 5-year low of 6.09.
The historical rank and industry rank for Lepu Biopharma Co's PS Ratio or its related term are showing as below:
HKSE:02157'
s PS Ratio Range Over the Past 10 Years
Min: 6.09 Med: 23.42 Max: 688.18
Current: 6.15
During the past 7 years, Lepu Biopharma Co's highest PS Ratio was 688.18. The lowest was 6.09. And the median was 23.42.
HKSE:02157's PS Ratio is ranked better than 60.84% of 932
companies
in the Biotechnology industry
Industry Median: 9.49
vs HKSE:02157: 6.15
During the past 7 years, Lepu Biopharma Co's highest 3-Year average Revenue per Share Growth Rate was 276.70% per year. The lowest was 276.70% per year. And the median was 276.70% per year.
Lepu Biopharma Co (HKSE:02157) PS Ratio Explanation
The PS Ratio is an excellent valuation indicator if you want to compare a stock with its historical valuation or with the stocks in the same industry. The PS Ratio works especially well when you want to compare the stock's current valuation with its historical valuation. The PS Ratio is a great valuation tool for evaluating cyclical businesses where the PE Ratio works poorly. It works the best when comparing the current valuation with the historical valuation because over time, a company's profit margin tends to revert to the mean.
When the PS Ratio is applied to the whole stock market, it can be used to evaluate the current market valuation and projected returns. In this case, the price is the total market cap of all stocks that are traded, and sales are the GDP of the country. This is how Warren Buffett estimates the broad market valuation and project future returns.
The PS Ratio does not tell you how cheap or expensive the stock is. It cannot be used to compare companies in different industries. It works better for companies within the same industry because these companies tend to have similar capital structures and profit margins. It works the best when comparing a company with itself in the past.
Lepu Biopharma Co PS Ratio Related Terms
Lepu Biopharma Co PS Ratio Historical Data
* Premium members only.
The historical data trend for Lepu Biopharma Co's PS Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
HKSE:02157 vs VRTX, REGN, RVMD: PS Ratio Comparison
For the Biotechnology subindustry, Lepu Biopharma Co's PS Ratio, along with its competitors' market caps and PS Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Lepu Biopharma Co PS Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Lepu Biopharma Co's PS Ratio distribution charts can be found below:
* The bar in red indicates where Lepu Biopharma Co's PS Ratio falls into.
The PS Ratio, or Price-to-Sales ratio, or Price/Sales, is a financial ratio used to compare a company's market price to its Revenue per Share. It is a ratio widely used to value stocks and it was first used by Ken Fisher.
Lepu Biopharma Co's Share Price of today is HK$3.83.
For company reported semi-annually, GuruFocus uses latest annual data as the TTM data. Lepu Biopharma Co's Revenue per Share for the trailing twelve months (TTM) ended in Dec. 2025 was HK$0.62.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
It can also be calculated from the numbers for the whole company:
Lepu Biopharma Co (HKSE:02157) has a PS Ratio of 6.15 as of Aug. 24, 2026. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lepu Biopharma Co and its competitors. This is 74% below median its historical median of 23.42. Over the past decade, Lepu Biopharma Co's PS Ratio has ranged from 6.09 to 688.18. According to the industry distribution chart, Lepu Biopharma Co ranks #365 out of 932 companies in the Biotechnology industry, placing it in the top 39.2%.
Is Lepu Biopharma Co's PS Ratio too high?
Lepu Biopharma Co's current PS Ratio of 6.15 is 74% below median its 10-year median of 23.42. Over the past 10 years, this metric has ranged from a low of 6.09 to a high of 688.18. The Biotechnology industry median PS Ratio is 9.49. Lepu Biopharma Co's value of 6.15 is 35.2% below this industry median. Based on the distribution chart, Lepu Biopharma Co ranks #365 out of 932 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Lepu Biopharma Co has a GF Score™ of 45/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Lepu Biopharma Co's PS Ratio compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, Lepu Biopharma Co ranks #365 out of 932 companies for PS Ratio. This puts Lepu Biopharma Co in the upper half of its industry. The industry median PS Ratio is 9.49. Lepu Biopharma Co's value of 6.15 is 35.2% below this benchmark. Historically, Lepu Biopharma Co's own PS Ratio has ranged from 6.09 to 688.18 over the past decade. While the company's 10-year median is 23.42 vs. the industry median of 9.49, Lepu Biopharma Co has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good PS Ratio for a Biotechnology company?
The median PS Ratio among Biotechnology companies is 9.49, based on 932 companies in the industry. Companies in the top quartile (top 25%) have a PS Ratio significantly above this median, while those in the bottom quartile fall well below. However, PS Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Lepu Biopharma Co's current PS Ratio of 6.15 is 35.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high PS Ratio mean?
A high PS Ratio can signal that a stock is expensive relative to its fundamentals. Price-to-Sales ratio is the ratio of share price to a company's revenue per share. View historical data on Lepu Biopharma Co and its competitors. For the Biotechnology industry, the median PS Ratio is 9.49 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Lepu Biopharma Co's current PS Ratio is 6.15, which is 74% below median its own 10-year median of 23.42. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Lepu Biopharma Co stock overvalued right now?
Based on GuruFocus' analysis, Lepu Biopharma Co (HKSE:02157) is currently considered Possible Value Trap. The stock's GF Value™ is HK$16.73, compared to a current price of HK$3.83 — trading 77.1% below its estimated fair value. The current PS Ratio is 6.15, which is 74% below median its 10-year median of 23.42 and 35.2% below the Biotechnology industry median of 9.49. Lepu Biopharma Co's overall GF Score™ is 45/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is PS Ratio calculated?
PS Ratio is calculated from a company's financial statements. For Lepu Biopharma Co (HKSE:02157), the current PS Ratio is 6.15 as of Aug. 24, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Lepu Biopharma Co (HKSE:02157) Overvalued in 2026?
Based on GuruFocus' analysis, Lepu Biopharma Co stock appears to be undervalued.
The current stock price of HK$3.83 is trading 77.1% below its estimated GF Value™ of HK$16.73.
GuruFocus considers Lepu Biopharma Co to be Possible Value Trap.
Key valuation signals for HKSE:02157:
PS Ratio: 6.15 (74% below median its 10-year median of 23.42)
GF Value™: HK$16.73 vs. price of HK$3.83 (77.1% below fair value)
Industry Position: 35.2% below the Biotechnology median (#365 of 932)
No single metric tells the full story. See the HKSE:02157 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Lepu Biopharma Co Ltd is focused on discovering, developing, and commercializing drug candidates in anti-tumor targeted therapy and oncology immunotherapy. Its commercial products include Puyouheng (Pucotenlimab Injection) and Meiyouheng (Becotatug Vedotin Injection). In addition, two other products, CMG901 and MRG007, have also been licensed out through its business development activities. Additionally, the company has several clinical-stage drug candidates and clinical-stage combination therapies of candidates, which are being developed as targeted therapeutics and immunotherapeutics. The various drug candidates in its pipeline include MRG003, MRG002, MRG004A, CG0070, MRG001, and MRG006A, among others. Geographically, the company generates maximum revenue from the Chinese mainland.
45GF Score
Get the complete analysis for HKSE:02157
PS Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
HKSE:02157 has been successfully added to your 
